2024
Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial
Kondo T, Mogensen U, Talebi A, Gasparyan S, Campbell R, Docherty K, de Boer R, Inzucchi S, Køber L, Kosiborod M, Martinez F, Sabatine M, Bengtsson O, Sjöstrand M, Vaduganathan M, Solomon S, Jhund P, McMurray J. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial. Journal Of The American College Of Cardiology 2024, 83: 1973-1986. PMID: 38537918, DOI: 10.1016/j.jacc.2024.03.385.Peer-Reviewed Original ResearchConceptsDAPA-HFLeft ventricular ejection fractionNYHA functional class IIEfficacy of dapagliflozinFunctional class IIIV heart failureVentricular ejection fractionEffects of dapagliflozinHeart failure hospitalizationDAPA-HF trialWell-beingFollow-up daysBetween-treatment differencesDapagliflozin groupPlacebo groupTime-to-first-event analysisEjection fractionFailure hospitalizationPatient well-beingHeart failureCardiovascular deathDapagliflozinRecurrent hospitalizationsClass IIPlaceboCardiac And Kidney Benefits Of Dapagliflozin Are Associated With ApoM Levels In Patients With Heart Failure With Reduced Ejection Fraction
Chang J, Javaheri A, Sauer A, Windsor S, Fu Z, Jones P, Margulies K, Lanfear D, Nassif M, Husain M, Inzucchi S, McGuire D, Pitt B, Scirica B, Kosiborod M. Cardiac And Kidney Benefits Of Dapagliflozin Are Associated With ApoM Levels In Patients With Heart Failure With Reduced Ejection Fraction. Journal Of Cardiac Failure 2024, 30: 236. DOI: 10.1016/j.cardfail.2023.10.284.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2 inhibitorsUrine albumin-creatinine ratioLog-transformed NT-proBNPLog-transformed NT-proBNP levelsDapagliflozin-treated patientsNT-proBNP levelsReduced ejection fractionNT-proBNPHeart failureApoM levelsEjection fractionType 2 diabetes mellitusPlacebo-treated patientsAlbumin-creatinine ratioCotransporter 2 inhibitorsEffect of dapagliflozinMultivariable linear regressionSphingosine-1-PhosphateKidney benefitsSGLT2i dapagliflozinDapagliflozin groupHF trialsPlacebo groupDapagliflozin treatmentOverall cohort
2020
The effect of dapagliflozin in patients with HFrEF and COPD: a post-hoc analysis of DAPA-HF
Dewan P, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Lindholm D, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. The effect of dapagliflozin in patients with HFrEF and COPD: a post-hoc analysis of DAPA-HF. European Heart Journal 2020, 41: ehaa946.0932. DOI: 10.1093/ehjci/ehaa946.0932.Peer-Reviewed Original ResearchChronic obstructive pulmonary diseaseEffect of dapagliflozinPrimary composite outcomeDAPA-HFHeart failureCV deathPlacebo groupComposite outcomeHazard ratioSodium-glucose cotransporter 2 inhibitorsAdditional effective therapiesReduced ejection fractionCotransporter 2 inhibitorsObstructive pulmonary diseaseCardiovascular deathDapagliflozin groupImportant comorbidityEjection fractionPrimary outcomePulmonary diseaseHF eventsSuboptimal treatmentWorse outcomesEffective therapyReduced risk
2019
P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease
McGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, Von Eynatten M, Johansen O, Elsasser U, Pocock S, Fitchett D, Jamal W, Hantel S, Lund S. P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease. European Heart Journal 2019, 40: ehz746.0869. DOI: 10.1093/eurheartj/ehz746.0869.Peer-Reviewed Original ResearchEMPA-REG OUTCOME trialEffect of empagliflozinCause hospitalisationType 2 diabetesHospitalisation eventsOutcome trialsHeart failureCardiovascular diseaseMajor adverse CV eventsTotal burdenAdjusted hazard ratioAdverse CV eventsAtherosclerotic cardiovascular diseaseCox regression modelStandard of careEvent rate ratioCV deathCV eventsEmpagliflozin groupPlacebo patientsRecurrent hospitalisationsCV diseasePlacebo groupFirst eventHazard ratio159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME
ZINMAN B, FITCHETT D, MATTHEUS M, WANNER C, GEORGE J, VEDIN O, INZUCCHI S, JOHANSEN O. 159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-159-lb.Peer-Reviewed Original ResearchEMPA-REG OUTCOMEAdverse eventsBoehringer Ingelheim PharmaceuticalsPlasma glucoseMyocardial infarctionCause deathCV outcomesJanssen PharmaceuticalsType 2 diabetes mellitusEli LillyRisk of MIHeart failure hospitalizationRisk of HHFCardio-protective effectsCox regression modelAdvisory PanelCV deathCV diseaseFailure hospitalizationPlacebo groupDiabetes mellitusDohme Corp.Novo Nordisk A/STime-varying covariatesMerck Sharp
2016
LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE
Lee D, Monteiro P, Clark D, Hantel S, Woerle H, Inzucchi S, Fitchett D. LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE. Journal Of Hypertension 2016, 34: e520. DOI: 10.1097/01.hjh.0000501423.64635.bd.Peer-Reviewed Original ResearchHeart failure hospitalizationHigh cardiovascular riskCardiovascular deathFailure hospitalizationHeart failureStandard of careType 2 diabetesEmpagliflozin groupCardiovascular riskMajor adverse cardiovascular eventsEMPA-REG OUTCOME trialEMPA-REG OUTCOMEAdverse cardiovascular eventsEffect of empagliflozinHeart failure outcomesMedian observation timeRisk of hospitalizationCardiovascular eventsPlacebo groupAdverse eventsEffect of ageOutcome trialsSafety profileMean ageBaseline age